Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus O Butler

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
Cancers|June 2, 2021
Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma PatientsSarah Zhou, Daniel Sikorski, Honghao Xu, et al.
Oncoimmunology|May 15, 2024
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumorsDouglas C Chung, Maryam Ghaedi, Kathrin Warner, et al.
Cancer Medicine|March 3, 2020
Cancer patients' experiences with immune checkpoint modulators: A qualitative studyKari Ala-Leppilampi, Natalie A Baker, Chris McKillop, et al.
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, et al.
Nature Biotechnology|March 2, 2021
Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4<sup>+</sup> T cellsKenji Sugata, Yukiko Matsunaga, Yuki Yamashita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
Cancers|June 2, 2021
Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma PatientsSarah Zhou, Daniel Sikorski, Honghao Xu, et al.
Oncoimmunology|May 15, 2024
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumorsDouglas C Chung, Maryam Ghaedi, Kathrin Warner, et al.
Cancer Medicine|March 3, 2020
Cancer patients' experiences with immune checkpoint modulators: A qualitative studyKari Ala-Leppilampi, Natalie A Baker, Chris McKillop, et al.
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, et al.
Nature Biotechnology|March 2, 2021
Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4<sup>+</sup> T cellsKenji Sugata, Yukiko Matsunaga, Yuki Yamashita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Pageof 13